Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14005311 | 0.97 | CXCR4 (0.51) | CXCR4TAAR1OPRK1CYP2D6TSHR | |
| SCHEMBL4892312 | 0.89 | CXCR4 (0.45) | CXCR4TAAR1OPRK1HDAC1SMN1; SMN2 | |
| SCHEMBL14005308 | 0.85 | HDAC1 (0.44) | CXCR4TAAR1OPRK1CYP2D6TSHR | |
| SCHEMBL14030731 | 0.85 | CXCR4 (0.39) | CXCR4TAAR1OPRK1CYP2D6TSHR | |
| SCHEMBL4892318 | 0.79 | HDAC1 (0.38) | CXCR4TAAR1OPRK1HDAC1SMN1; SMN2 | |
| SCHEMBL1206171 | 0.77 | CXCR4 (0.49) | CXCR4OPRK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4890220 | 0.75 | CXCR4 (0.42) | CXCR4TAAR1OPRK1CYP2D6TSHR | |
| SCHEMBL14005298 | 0.73 | PTGS2 (0.44) | OPRK1HDAC1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL4890154 | 0.73 | OPRK1 (0.46) | OPRK1HDAC1SMN1; SMN2HDAC6 | |
| SCHEMBL1793193 | 0.71 | CXCR4 (1.00) | CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| WO-2008112156-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | CXCR4 3/4885TAAR1 1220/4885OPRK1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.